[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 33 of about 33
1. van den Bogaert DP, Pouw EM, van Wijhe G, Vernhout RM, Surmont VF, Hoogsteden HC, van Klaveren RJ: Pemetrexed maintenance therapy in patients with malignant pleural mesothelioma. J Thorac Oncol; 2006 Jan;1(1):25-30
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pemetrexed maintenance therapy in patients with malignant pleural mesothelioma.
  • PURPOSE: To investigate the toxicity and effectiveness of pemetrexed maintenance therapy (PMT) in patients with malignant pleural mesothelioma (MPM).
  • PATIENTS AND METHODS: Eligible were patients with histologically proven advanced MPM, WHO PS 0-2 and adequate hematological, renal and hepatic function in whom during 6 courses of pemetrexed containing induction therapy no disease progression was observed.
  • RESULTS: Of the 27 patients who received induction therapy, 13 were treated with PMT.
  • During PMT 23% of the patients with stable disease after induction therapy achieved a partial response.
  • Time to progression and overall survival were 3.4 and 6.0 months versus 8.5 and 17.9 months, respectively (p < 0.0001).
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Glutamates / therapeutic use. Guanine / analogs & derivatives. Mesothelioma / drug therapy. Pleural Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Disease Progression. Dose-Response Relationship, Drug. Drug Administration Schedule. Feasibility Studies. Female. Follow-Up Studies. Humans. Injections, Intravenous. Male. Middle Aged. Neoplasm Staging. Netherlands / epidemiology. Pemetrexed. Retrospective Studies. Survival Rate / trends. Thymidylate Synthase / antagonists & inhibitors. Treatment Outcome

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • Hazardous Substances Data Bank. PEMETREXED .
  • Hazardous Substances Data Bank. GUANINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17409823.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Glutamates; 04Q9AIZ7NO / Pemetrexed; 5Z93L87A1R / Guanine; EC 2.1.1.45 / Thymidylate Synthase
  •  go-up   go-down


2. Silva RG, Dahmoush L, Gerke H: Pancreatic metastasis of an ovarian malignant mixed Mullerian tumor identified by EUS-guided fine needle aspiration and Trucut needle biopsy. JOP; 2006;7(1):66-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pancreatic metastasis of an ovarian malignant mixed Mullerian tumor identified by EUS-guided fine needle aspiration and Trucut needle biopsy.
  • CONTEXT: Malignant mixed Mullerian tumors are rare ovarian neoplasms that account for less than 2% of ovarian malignancies.
  • To our knowledge, this is the first report of a malignant mixed Mullerian tumor with metastasis to the pancreas.
  • The metastatic tumor was identified by endoscopic ultrasound guided fine needle aspiration (EUS-FNA) and Trucut needle biopsy of the pancreas.
  • CASE REPORT: We describe a 69-year-old female with concomitant Duke's C adenocarcinoma of the colon and stage III-C malignant mixed Mullerian tumor that presented with malignant ascites, increasing abdominal girth and a pancreatic head mass.
  • EUS revealed an 11 cm cystic mass in the head of the pancreas that was characterized as a carcinosarcoma/malignant mesodermal mixed tumor by EUS-FNA and Trucut needle biopsy.
  • The tumor was morphologically identical to the surgical specimen of her ovarian mass.
  • The patient was treated with palliative chemotherapy and a three-month follow up CT scan did not reveal any new metastatic lesions.
  • CONCLUSION: The pancreas is a rare site of metastasis and more commonly seen in renal cell carcinoma, melanoma or lung tumors; amongst others.
  • Although ovarian adenocarcinoma has been reported as a primary site of pancreatic metastasis, it has not been previously described originating from a mixed Mullerian tumor of the ovary presenting as a cystic pancreatic head mass.
  • [MeSH-major] Mixed Tumor, Mullerian / secondary. Ovarian Neoplasms / pathology. Pancreatic Neoplasms / secondary
  • [MeSH-minor] Aged. Biopsy, Fine-Needle / methods. Endosonography. Female. Humans. Neoplasm Staging. Pancreas / pathology. Pancreas / radiography. Prognosis. Tomography, X-Ray Computed


3. McClay EF, McClay ME, Monroe L, Baron PL, Cole DJ, O'Brien PH, Metcalf JS, Maize JC: The effect of tamoxifen and cisplatin on the disease-free and overall survival of patients with high risk malignant melanoma. Br J Cancer; 2000 Jul;83(1):16-21
Hazardous Substances Data Bank. DEXAMETHASONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The effect of tamoxifen and cisplatin on the disease-free and overall survival of patients with high risk malignant melanoma.
  • The adjuvant treatment of high-risk malignant melanoma remains problematic.
  • Previously we reported moderate success in the treatment of metastatic disease using tamoxifen, cisplatin, dacarbazine and carmustine.
  • During the first 2 years of follow-up, patients were evaluated every 2 months with a history, physical exam, laboratory work and computed tomography scans of the chest, abdomen and pelvis every 4 months.
  • No effect of gender or number of positive lymph nodes was noted, however, stage of disease prior treatment was a factor.
  • Minimal renal, haematologic and neurologic toxicity occurred.
  • These preliminary results suggest that there is a positive impact of tamoxifen and cisplatin on both the DFS and OS of high-risk malignant melanoma patients.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Melanoma / drug therapy. Skin Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Antiemetics / therapeutic use. Cisplatin / administration & dosage. Cisplatin / adverse effects. Combined Modality Therapy. Dexamethasone / therapeutic use. Disease-Free Survival. Female. Follow-Up Studies. Granisetron / therapeutic use. Humans. Life Tables. Lymphatic Metastasis. Male. Middle Aged. Nausea / chemically induced. Nausea / prevention & control. Neoplasm Metastasis. Neoplasm Staging. Ondansetron / therapeutic use. Prognosis. Risk. Survival Analysis. Tamoxifen / administration & dosage. Tamoxifen / adverse effects. Treatment Outcome. Vomiting / chemically induced. Vomiting / prevention & control

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TAMOXIFEN .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Cancer Inst. 1989 Dec 20;81(24):1893-904 [2593166.001]
  • [Cites] Cancer. 1989 Apr 1;63(7):1292-5 [2920358.001]
  • [Cites] J Clin Oncol. 1991 May;9(5):736-40 [2016616.001]
  • [Cites] Cancer. 1992 Jan 15;69(2):427-9 [1728371.001]
  • [Cites] Int J Cancer. 1992 Feb 20;50(4):553-6 [1537621.001]
  • [Cites] N Engl J Med. 1992 Aug 20;327(8):516-23 [1635566.001]
  • [Cites] Ann Plast Surg. 1992 Jan;28(1):65-9 [1642409.001]
  • [Cites] Cancer Res. 1992 Dec 15;52(24):6790-6 [1458467.001]
  • [Cites] Cancer Res. 1993 Apr 1;53(7):1571-6 [8453625.001]
  • [Cites] Eur J Cancer. 1993;29A(9):1237-42 [8343260.001]
  • [Cites] Cancer. 1993 Sep 15;72(6):1914-8 [8364868.001]
  • [Cites] Int J Cancer. 1993 Dec 2;55(6):1018-22 [8253520.001]
  • [Cites] Am J Clin Oncol. 1994 Feb;17(1):55-9 [8311008.001]
  • [Cites] Lancet. 1994 Apr 9;343(8902):913-4 [7908370.001]
  • [Cites] Cancer. 1994 Apr 15;73(8):2119-30 [8156517.001]
  • [Cites] Br J Cancer. 1994 Sep;70(3):449-52 [8080729.001]
  • [Cites] J Clin Oncol. 1995 Nov;13(11):2776-83 [7595738.001]
  • [Cites] J Clin Oncol. 1996 Jan;14(1):7-17 [8558223.001]
  • [Cites] Oncology (Williston Park). 1995 Nov;9(11):1149-58; discussion 1163-4, 1167-8 [8703684.001]
  • [Cites] J Clin Oncol. 1996 Jul;14(7):2083-90 [8683240.001]
  • [Cites] J Clin Oncol. 1996 Oct;14(10):2666-73 [8874325.001]
  • [Cites] J Clin Oncol. 1998 Apr;16(4):1425-9 [9552047.001]
  • [Cites] J Clin Oncol. 1991 May;9(5):729-35 [2016615.001]
  • [Cites] J Clin Oncol. 1999 Jun;17(6):1884-90 [10561229.001]
  • [Cites] Cancer Treat Rep. 1984 Nov;68(11):1403-5 [6541973.001]
  • [Cites] Cancer Treat Rep. 1987 May;71(5):465-9 [3567970.001]
  • [CommentIn] Br J Cancer. 2000 Jul;83(1):6-7 [10883660.001]
  • (PMID = 10883662.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA52151
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Comparative Study; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] SCOTLAND
  • [Chemical-registry-number] 0 / Antiemetics; 094ZI81Y45 / Tamoxifen; 4AF302ESOS / Ondansetron; 7S5I7G3JQL / Dexamethasone; Q20Q21Q62J / Cisplatin; WZG3J2MCOL / Granisetron
  • [Other-IDs] NLM/ PMC2374536
  •  go-up   go-down


Advertisement
4. Morgan GJ, Davies FE, Gregory WM, Cocks K, Bell SE, Szubert AJ, Navarro-Coy N, Drayson MT, Owen RG, Feyler S, Ashcroft AJ, Ross F, Byrne J, Roddie H, Rudin C, Cook G, Jackson GH, Child JA, National Cancer Research Institute Haematological Oncology Clinical Study Group: First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial. Lancet; 2010 Dec 11;376(9757):1989-99
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial.
  • BACKGROUND: Bisphosphonates reduce the risk of skeletal events in patients with malignant bone disease, and zoledronic acid has shown potential anticancer effects in preclinical and clinical studies.
  • Patients also received intensive or non-intensive induction chemotherapy.
  • No investigators, staff, or patients were masked to treatment allocation, and bisphosphonate and maintenance therapy continued at least until disease progression.
  • FINDINGS: 1970 patients were enrolled between May, 2003, and November, 2007, of whom 1960 were eligible for intention-to-treat analysis: 981 in the zoledronic acid group (555 on intensive chemotherapy, 426 on non-intensive chemotherapy); and 979 on clodronic acid (556 on intensive chemotherapy, 423 on non-intensive chemotherapy).
  • The treatment cutoff was Oct 5, 2009, with patients receiving bisphosphonates for a median of 350 days (IQR 137-632) before disease progression, with a median of 3·7 years' follow-up (IQR 2·9-4·7).
  • Rates of complete, very good partial, or partial response did not differ significantly between the zoledronic acid and clodronic acid groups for patients receiving intensive induction chemotherapy (432 patients [78%] vs 422 [76%]; p=0·43) or non-intensive induction chemotherapy (215 [50%] vs 195 [46%]; p=0·18).
  • Both bisphosphonates were generally well tolerated, with similar occurrence of acute renal failure and treatment-emergent serious adverse events, but zoledronic acid was associated with higher rates of confirmed osteonecrosis of the jaw (35 [4%]) than was clodronic acid (3 [<1%]).
  • INTERPRETATION: Consistent with the potential anticancer activity of zoledronic acid, overall survival improved independently of prevention of skeletal-related events, showing that zoledronic acid has treatment benefits beyond bone health.
  • These findings support immediate treatment with zoledronic acid in patients with newly diagnosed multiple myeloma, not only for prevention of skeletal-related events, but also for potential antimyeloma benefits.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Bone Density Conservation Agents / therapeutic use. Bone Neoplasms / prevention & control. Clodronic Acid / therapeutic use. Diphosphonates / therapeutic use. Imidazoles / therapeutic use. Multiple Myeloma / drug therapy
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Disease-Free Survival. Drug Administration Schedule. Female. Humans. Infusions, Intravenous. Kaplan-Meier Estimate. Logistic Models. Male. Middle Aged. Neoplasm Staging. Odds Ratio. Proportional Hazards Models. Research Design. Treatment Outcome. United Kingdom

  • Genetic Alliance. consumer health - Multiple myeloma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Ltd. All rights reserved.
  • [Cites] Cancer. 2008 Oct 1;113(7):1588-95 [18683218.001]
  • [Cites] Cancer Treat Rev. 2008 Aug;34(5):453-75 [18423992.001]
  • [Cites] Ann Oncol. 2009 Jan;20(1):137-45 [18647964.001]
  • [Cites] Ann Oncol. 2009 Jan;20(1):117-20 [18689864.001]
  • [Cites] N Engl J Med. 2009 Feb 12;360(7):679-91 [19213681.001]
  • [Cites] Ann Oncol. 2009 Aug;20(8):1303-17 [19465418.001]
  • [Cites] Clin Lymphoma Myeloma. 2009 Aug;9(4):278-88 [19717377.001]
  • [Cites] Lancet Oncol. 2009 Sep;10(9):872-6 [19674936.001]
  • [Cites] Int J Cancer. 2010 Jan 1;126(1):239-46 [19621390.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2009;:555-65 [20008240.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2009;:566-77 [20008241.001]
  • [Cites] Leukemia. 2009 Dec;23(12):2210-21 [19798094.001]
  • [Cites] Ann Oncol. 2010 Nov;21(11):2188-94 [20444845.001]
  • [Cites] Leuk Lymphoma. 2008 Nov;49(11):2156-62 [19021059.001]
  • [Cites] BMC Clin Pharmacol. 2008;8:2 [18377658.001]
  • [Cites] Med Oncol. 2007;24(2):227-30 [17848748.001]
  • [Cites] Br J Haematol. 2001 Jun;113(4):1035-43 [11442499.001]
  • [Cites] Cancer J. 2001 Sep-Oct;7(5):377-87 [11693896.001]
  • [Cites] J Bone Miner Res. 2003 Mar;18(3):482-92 [12619933.001]
  • [Cites] N Engl J Med. 2003 May 8;348(19):1875-83 [12736280.001]
  • [Cites] Cancer. 2003 Oct 15;98(8):1735-44 [14534891.001]
  • [Cites] Oncologist. 2004;9 Suppl 4:3-13 [15459425.001]
  • [Cites] J Clin Oncol. 1998 Feb;16(2):593-602 [9469347.001]
  • [Cites] Hematology. 2005 Jun;10(3):215-24 [16019470.001]
  • [Cites] Leukemia. 2006 Sep;20(9):1467-73 [16855634.001]
  • [Cites] Blood. 2006 Nov 15;108(10):3289-94 [16873668.001]
  • [Cites] Cancer Biol Ther. 2006 Sep;5(9):1082-5 [16969119.001]
  • [Cites] Crit Rev Oncol Hematol. 2007 May;62(2):148-52 [17336086.001]
  • [Cites] Expert Opin Drug Saf. 2007 May;6(3):305-13 [17480179.001]
  • [Cites] J Clin Oncol. 2007 Jun 10;25(17):2464-72 [17515569.001]
  • [Cites] Clin Lymphoma Myeloma. 2007 Mar;7(5):346-53 [17562244.001]
  • [Cites] Int J Lab Hematol. 2007 Oct;29(5):395-7 [17824924.001]
  • [CommentIn] Lancet. 2011 Jun 25;377(9784):2178 [21704866.001]
  • [CommentIn] Lancet. 2011 Jun 25;377(9784):2177-8 [21704864.001]
  • [CommentIn] Lancet. 2010 Dec 11;376(9757):1965-6 [21131042.001]
  • (PMID = 21131037.001).
  • [ISSN] 1474-547X
  • [Journal-full-title] Lancet (London, England)
  • [ISO-abbreviation] Lancet
  • [Language] eng
  • [Databank-accession-numbers] ISRCTN/ ISRCTN68454111
  • [Grant] United Kingdom / Medical Research Council / / G0100132; United Kingdom / Medical Research Council / /
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Bone Density Conservation Agents; 0 / Diphosphonates; 0 / Imidazoles; 0813BZ6866 / Clodronic Acid; 6XC1PAD3KF / zoledronic acid
  • [Other-IDs] NLM/ PMC3639680
  • [Investigator] Russell NH; Cook G; Roddie H; Rudin C; Milligan DW; Snowden J; Sayala H; Chu P; Wright D; Gelly K; Turner D; Jackson H; Craig J; Tighe J; Shafeek S; Neilson J; Cavet J; McKernan A; Kruger A; Macheta MP; Wood A; Smith A
  •  go-up   go-down


5. Hosokawa Y, Saiki S, Hanafusa T, Meguro N, Maeda O, Kinouchi T, Kuroda M, Usami M, Kotake T: [A case of adult Wilms' tumor]. Hinyokika Kiyo; 2001 Sep;47(9):641-3
Hazardous Substances Data Bank. IFOSFAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of adult Wilms' tumor].
  • Wilms' tumor is very rarely found in adults and there are no established treatment guidelines for such tumors in adults.
  • Computed tomography scan revealed a large right renal mass with enlarged lymph nodes.
  • Angiography showed a hypovascular tumor.
  • She underwent right nephrectomy and resection of lymph node metastasis with a diagnosis of malignant renal tumor.
  • The disease was classified as stage III according to the National Wilms' Tumor Study classification.
  • The patient received adjuvant chemotherapy consisting of ifosfamide, cisplatin, and etoposide.
  • This protocol was selected because of the published poor results with the standard Wilms' tumor chemotherapeutic agents when used in adults.
  • She remained without tumor recurrence as of six months after surgery.
  • Development of better therapeutic approaches to adult Wilms' tumor is awaited.
  • [MeSH-major] Kidney Neoplasms / therapy. Wilms Tumor / therapy
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Etoposide / administration & dosage. Female. Humans. Ifosfamide. Lymph Node Excision. Lymphatic Metastasis. Middle Aged. Neoplasm Staging. Nephrectomy. Treatment Outcome

  • Genetic Alliance. consumer health - Wilms' tumor.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Wilms Tumor.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11692602.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin; UM20QQM95Y / Ifosfamide
  • [Number-of-references] 12
  •  go-up   go-down


6. Willmott F, Agarwal N, Heath M, Stevens J, Chakravarti S: Plasma cell myeloma diagnosed in pregnancy. BMJ Case Rep; 2010;2010
MedlinePlus Health Information. consumer health - Tumors and Pregnancy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The clinical picture is one of bone marrow failure, due to infiltration of the marrow by malignant plasma cells; renal failure due to damage to renal tubules by the excess light chains and pain due to lytic lesions of the bones.
  • [MeSH-major] Multiple Myeloma / diagnosis. Pregnancy Complications, Neoplastic / diagnosis
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biopsy, Needle. Bone Marrow / pathology. Cesarean Section. Disease Progression. Female. Fetal Growth Retardation / diagnosis. Hematopoietic Stem Cell Transplantation. Humans. Infant, Newborn. Male. Neoplasm Staging. Pregnancy. Puerperal Disorders / diagnosis. Puerperal Disorders / drug therapy. Puerperal Disorders / pathology. Remission Induction

  • Genetic Alliance. consumer health - Pregnancy.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Bone Joint Surg Am. 2004 Jun;86-A(6):1284-8 [15173303.001]
  • [Cites] Blood. 1966 Jul;28(1):102-11 [5944257.001]
  • [Cites] Obstet Gynecol. 1968 Jun;31(6):811-20 [5742077.001]
  • [Cites] West Indian Med J. 1971 Jun;20(2):97-100 [5110487.001]
  • [Cites] Cancer. 1974 Oct;34(4):1018-22 [4417641.001]
  • [Cites] Arch Pathol Lab Med. 1987 Jan;111(1):38-42 [3800603.001]
  • [Cites] Obstet Gynecol. 1990 Mar;75(3 Pt 2):513-5 [2304725.001]
  • [Cites] Obstet Gynecol. 1990 Mar;75(3 Pt 2):516-8 [2304726.001]
  • [Cites] Int J Gynaecol Obstet. 1991 Aug;35(4):341-2 [1682183.001]
  • [Cites] Am J Obstet Gynecol. 1995 Jan;172(1 Pt 1):217-9 [7847542.001]
  • [Cites] Leuk Res. 1997 Sep;21(9):885-8 [9393604.001]
  • [Cites] J Clin Oncol. 2005 May 20;23(15):3412-20 [15809451.001]
  • [Cites] Am J Clin Pathol. 2005 Jul;124(1):108-12 [15923168.001]
  • [Cites] J Obstet Gynaecol. 2006 Oct;26(7):693-5 [17071446.001]
  • [Cites] Nephrol Dial Transplant. 2007 Dec;22(12):3652-5 [17875572.001]
  • [Cites] Int J Gynaecol Obstet. 2008 Jan;100(1):89-90 [17825829.001]
  • [Cites] Ann Hematol. 2009 Feb;88(2):181-2 [18682949.001]
  • [Cites] Eur J Obstet Gynecol Reprod Biol. 2003 Dec 10;111(2):214-5 [14597255.001]
  • (PMID = 22791481.001).
  • [ISSN] 1757-790X
  • [Journal-full-title] BMJ case reports
  • [ISO-abbreviation] BMJ Case Rep
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC3027817
  •  go-up   go-down


7. Rudin CM, Holmlund J, Fleming GF, Mani S, Stadler WM, Schumm P, Monia BP, Johnston JF, Geary R, Yu RZ, Kwoh TJ, Dorr FA, Ratain MJ: Phase I Trial of ISIS 5132, an antisense oligonucleotide inhibitor of c-raf-1, administered by 24-hour weekly infusion to patients with advanced cancer. Clin Cancer Res; 2001 May;7(5):1214-20
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I Trial of ISIS 5132, an antisense oligonucleotide inhibitor of c-raf-1, administered by 24-hour weekly infusion to patients with advanced cancer.
  • Constitutive activation of this pathway directly contributes to malignant transformation in many human tumors.
  • This Phase I trial, involving 22 patients with advanced cancer, was designed to evaluate the safety, feasibility, and maximum tolerated dose of ISIS 5132 administration as a weekly 24-h i.v. infusion.
  • Two of four patients treated at 30 mg/kg/week had serious adverse events after the first dose of ISIS 5132, including acute hemolytic anemia and acute renal failure and anasarca.
  • These data suggest that the efficacy and toxicity profiles of antisense oligonucleotides may be highly dependent on the schedule of administration and support the analysis of the putative molecular target in the evaluation of novel therapeutics.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Neoplasms / drug therapy. Oligodeoxyribonucleotides, Antisense / therapeutic use. Proto-Oncogene Proteins c-raf / antagonists & inhibitors. Thionucleotides / therapeutic use
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Blood Coagulation / drug effects. Complement System Proteins / metabolism. Drug Administration Schedule. Female. Humans. Infusions, Intravenous. Leukocytes, Mononuclear / drug effects. Leukocytes, Mononuclear / metabolism. Male. Middle Aged. Neoplasm Staging. RNA, Messenger / antagonists & inhibitors. RNA, Messenger / blood. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11350886.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA14999; United States / NCI NIH HHS / CA / CA81134
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / ISIS 5132; 0 / Oligodeoxyribonucleotides, Antisense; 0 / RNA, Messenger; 0 / Thionucleotides; 9007-36-7 / Complement System Proteins; EC 2.7.11.1 / Proto-Oncogene Proteins c-raf
  •  go-up   go-down


8. Batchelor DJ, Bright SR, Ibarrola P, Tzannes S, Blackwood L: Long-term survival after combination chemotherapy for bilateral renal malignant lymphoma in a dog. N Z Vet J; 2006 Jun;54(3):147-50
MedlinePlus Health Information. consumer health - Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term survival after combination chemotherapy for bilateral renal malignant lymphoma in a dog.
  • CLINICAL FINDINGS AND DIAGNOSIS: Radiography and ultrasonography revealed bilateral renomegaly, and cytology of fine needle aspirates from the kidneys was diagnostic of malignant lymphoma.
  • The dog was treated with a modified high-dose cyclophosphamide-, vincristine-, and prednisolone-based chemotherapy protocol, achieved remission, and returned to normal quality of life.
  • Survival time was 346 days from the time of diagnosis.
  • CLINICAL RELEVANCE: Malignant lymphoma in the kidneys of dogs has been considered to carry a uniformly poor prognosis.
  • Long-term remission after medical treatment has not previously been reported.
  • The favourable outcome in this case illustrates the limitations of clinical staging in determining the outcome for individual patients.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Dog Diseases / drug therapy. Kidney Neoplasms / drug therapy. Lymphoma / drug therapy
  • [MeSH-minor] Animals. Dogs. Male. Neoplasm Staging. Prognosis. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16751846.001).
  • [ISSN] 0048-0169
  • [Journal-full-title] New Zealand veterinary journal
  • [ISO-abbreviation] N Z Vet J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] New Zealand
  •  go-up   go-down


9. Chiappori A, Simon G, Williams C, Haura E, Rocha-Lima C, Wagner H, Bepler G, Antonia S: Phase II study of first-line sequential chemotherapy with gemcitabine-carboplatin followed by docetaxel in patients with advanced non-small cell lung cancer. Oncology; 2005;68(4-6):382-90
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of first-line sequential chemotherapy with gemcitabine-carboplatin followed by docetaxel in patients with advanced non-small cell lung cancer.
  • RATIONALE: Despite the use of novel chemotherapeutic agents, patients with advanced non-small cell lung cancer (NSCLC) continue to show a poor survival.
  • OBJECTIVES: To assess the safety and efficacy of a novel sequential and putatively non-cross-resistant chemotherapy regimen.
  • METHODS: Eligibility included: stages IV and IIIB (malignant pleural effusion), performance status 0-1, and adequate renal, hepatic and bone marrow function.
  • Treatment consisted of gemcitabine, 1,000 mg/m2, on days 1 and 8, and carboplatin, AUC = 5, on day 1 every 4 weeks (2-4 cycles) followed by docetaxel, 75 mg/m2, on day 1 every 3 weeks (4 cycles).
  • Median survival time and progression-free survival were 6.7 and 4.9 months, respectively, with a 1-year survival of 37.5%.
  • Our results are comparable to those achieved with other similar regimens and do not represent a significant improvement in the treatment of advanced NSCLC.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Lung Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Carboplatin / administration & dosage. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Female. Humans. Male. Middle Aged. Neoplasm Staging. Survival Rate. Taxoids / administration & dosage. Treatment Outcome

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16020967.001).
  • [ISSN] 0030-2414
  • [Journal-full-title] Oncology
  • [ISO-abbreviation] Oncology
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Review
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Taxoids; 0W860991D6 / Deoxycytidine; 15H5577CQD / docetaxel; B76N6SBZ8R / gemcitabine; BG3F62OND5 / Carboplatin
  • [Number-of-references] 37
  •  go-up   go-down


10. Su WC, Lai WW, Chen HH, Hsiue TR, Chen CW, Huang WT, Chen TY, Tsao CJ, Wang NS: Combined intrapleural and intravenous chemotherapy, and pulmonary irradiation, for treatment of patients with lung cancer presenting with malignant pleural effusion. A pilot study. Oncology; 2003;64(1):18-24
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combined intrapleural and intravenous chemotherapy, and pulmonary irradiation, for treatment of patients with lung cancer presenting with malignant pleural effusion. A pilot study.
  • OBJECTIVES: Patients with non-small-cell lung cancer (NSCLC) and malignant pleural effusion (MPE) are difficult to manage clinically and have a short life expectancy.
  • In this pilot study, we designed a protocol of combined intrapleural (i.p.) and intravenous (i.v.) chemotherapy and pulmonary irradiation to enhance local as well as systemic control of the disease.
  • Patients received pre-radiation chemotherapy (cisplatin 60 mg/m(2) i.p. on day 1; gemcitabine 1,000 mg/m(2) i.v. on days 1, 8, and 15, q4week x 3) after surgical implantation of i.p. and i.v. port-A, followed by radiotherapy (7,020 cGy/39fr), and, finally, post-radiation chemotherapy (docetaxel 60 mg/m(2) q3week x 3-6 i.v.).
  • RESULTS: Grade 1/2 nausea/vomiting and impaired renal function were more common from pre-radiation than post-radiation chemotherapy; however, grade 3/4 toxicities from pre-radiation chemotherapy were minimal.
  • Conversely, grade 3/4 leukopenia and grade 1/2 alopecia, diarrhea, elevation of SGOT/SGPT, and sensory impairment were more common following post-radiation chemotherapy.
  • CONCLUSIONS: We conclude that the combination of i.p. and i.v. chemotherapy and pulmonary irradiation is feasible and should be tested in a larger clinical trial to determine whether survival can be improved for this cohort of patients.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Non-Small-Cell Lung / therapy. Deoxycytidine / analogs & derivatives. Lung Neoplasms / therapy. Pleural Effusion, Malignant / therapy
  • [MeSH-minor] Adult. Aged. Cisplatin / administration & dosage. Female. Humans. Infusions, Intravenous. Injections, Intralesional. Male. Middle Aged. Neoplasm Staging. Pilot Projects. Pleurodesis. Radiotherapy, Adjuvant. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2003 S. Karger AG, Basel
  • (PMID = 12457027.001).
  • [ISSN] 0030-2414
  • [Journal-full-title] Oncology
  • [ISO-abbreviation] Oncology
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


11. Sun YJ, Zhao H, Guo YW, Lin F, Cai X, Tang XC, Yao Y: [Short-term effects of chemotherapy with combination of hydroxycamptothecine and oxaliplatin in the treatment of advanced digestive tract cancers]. Zhonghua Zhong Liu Za Zhi; 2004 Dec;26(12):749-52
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Short-term effects of chemotherapy with combination of hydroxycamptothecine and oxaliplatin in the treatment of advanced digestive tract cancers].
  • OBJECTIVE: To evaluate the short-term therapeutic effects and side effects of combined hydroxycamptothecine and oxaliplatin in the treatment of advanced digestive tract cancers.
  • METHODS: Thirty patients suffering from advanced digestive tract tumors including gastric cancer 8, colorectal cancer 20, cholecystic cancer 1 and malignant fibroadenoma 1 were studied.
  • Diarrhea developed in 42 cycles (54.5%) and 20 cycles (47.6%) grades III and IV.
  • The other side effects were fever, alopecia, nausea and vomiting, constipation, hepatic and renal function abnormity and neuritis.
  • CONCLUSION: Satisfactory response rate is obtainable in advanced colorectal cancer as treated by hydroxycamptothecine plus oxaliplatin.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Colorectal Neoplasms / drug therapy. Liver Neoplasms / drug therapy. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / secondary. Adult. Aged. Camptothecin / administration & dosage. Camptothecin / analogs & derivatives. Diarrhea / chemically induced. Female. Humans. Leukopenia / chemically induced. Lung Neoplasms / drug therapy. Lung Neoplasms / secondary. Male. Middle Aged. Neoplasm Staging. Organoplatinum Compounds / administration & dosage. Remission Induction. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15733397.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin; 67656-30-8 / 10-hydroxycamptothecin; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


12. Kaste SC, Dome JS, Babyn PS, Graf NM, Grundy P, Godzinski J, Levitt GA, Jenkinson H: Wilms tumour: prognostic factors, staging, therapy and late effects. Pediatr Radiol; 2008 Jan;38(1):2-17
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Wilms tumour: prognostic factors, staging, therapy and late effects.
  • Wilms tumour is the most common malignant renal tumour in children.
  • Dramatic improvements in survival have occurred as the result of advances in anaesthetic and surgical management, irradiation and chemotherapy.
  • Current therapies are based on trials and studies primarily conducted by large multi-institutional cooperatives including the Société Internationale d'Oncologie Pédiatrique (SIOP) and the Children's Oncology Group (COG).
  • The primary goals are to treat patients according to well-defined risk groups in order to achieve the highest cure rates, to decrease the frequency and intensity of acute and late toxicity and to minimize the cost of therapy.
  • The SIOP trials and studies largely focus on the issue of preoperative therapy, whereas the COG trials and studies start with primary surgery.
  • This paper reviews prognostic factors and staging systems for Wilms tumour and its current treatment with surgery and chemotherapy.
  • Surgery remains a crucial part of treatment for nephroblastoma, providing local primary tumour control and adequate staging and possibly controlling the metastatic spread and central vascular extension of the disease.
  • The late effects for Wilms tumour and its treatment are also reviewed.
  • The treatment of Wilms tumour has been a success story, and currently in excess of 80% of children diagnosed with Wilms tumour can look forward to long-term survival, with less than 20% experiencing serious morbidity at 20 years from diagnosis.
  • The late complications are a consequence of the type and intensity of treatment required, which in turn reflects the nature and extent of the original tumour.
  • Continual international trial development and participation will improve matching of treatment needs with prognosis, reducing long-term complications in the majority.
  • [MeSH-major] Kidney Neoplasms / pathology. Kidney Neoplasms / therapy. Wilms Tumor / pathology. Wilms Tumor / therapy
  • [MeSH-minor] Child. Clinical Trials as Topic. Combined Modality Therapy. Humans. Male. Neoplasm Metastasis. Neoplasm Staging. Prognosis. Risk Factors. Survival Analysis

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Wilms Tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Pediatr Radiol. 2008 Apr;38(4):483; author reply 484-5 [18299824.001]
  • [CommentIn] Pediatr Radiol. 2008 Jan;38(1):1 [18026722.001]
  • [Cites] J Clin Oncol. 1983 Oct;1(10):604-9 [6321673.001]
  • [Cites] J Pediatr Surg. 2006 Apr;41(4):652-7; discussion 652-7 [16567171.001]
  • [Cites] Med Pediatr Oncol. 2002 Apr;38(4):258-9 [11920790.001]
  • [Cites] J Clin Oncol. 1995 Jul;13(7):1546-56 [7602343.001]
  • [Cites] Am J Pathol. 2001 Feb;158(2):393-8 [11159177.001]
  • [Cites] Cancer Res. 1999 Sep 1;59(17):4301-7 [10485476.001]
  • [Cites] N Engl J Med. 1987 Sep 3;317(10):588-93 [3475572.001]
  • [Cites] J Clin Oncol. 2001 Jan 15;19(2):488-500 [11208843.001]
  • [Cites] J Natl Cancer Inst. 1997 Aug 6;89(15):1089-91 [9262241.001]
  • [Cites] Int J Cancer. 1989 Mar 15;43(3):399-402 [2538400.001]
  • [Cites] J Pediatr Hematol Oncol. 2002 Mar-Apr;24(3):192-8 [11990305.001]
  • [Cites] Clin Oncol (R Coll Radiol). 1997;9(6):381-4 [9448966.001]
  • [Cites] Cancer. 1996 Aug 15;78(4):887-91 [8756386.001]
  • [Cites] J Urol. 2005 Oct;174(4 Pt 2):1519-21; discussion 1521 [16148643.001]
  • [Cites] Nat Rev Cancer. 2005 Sep;5(9):699-712 [16110318.001]
  • [Cites] Eur J Cancer. 2006 Mar;42(4):501-8 [16406574.001]
  • [Cites] J Natl Cancer Inst. 2001 Apr 18;93(8):618-29 [11309438.001]
  • [Cites] Ann Oncol. 2002 Mar;13(3):460-9 [11996479.001]
  • [Cites] J Clin Oncol. 1994 Oct;12(10):2126-31 [7931483.001]
  • [Cites] Ann Oncol. 2001 Mar;12(3):311-9 [11332141.001]
  • [Cites] J Natl Cancer Inst. 1996 Mar 6;88(5):270-8 [8614005.001]
  • [Cites] Pediatr Blood Cancer. 2006 Sep;47(3):232-4 [16830319.001]
  • [Cites] Surg Gynecol Obstet. 1992 Dec;175(6):507-14 [1333095.001]
  • [Cites] J Clin Oncol. 1990 Jul;8(7):1187-90 [2162911.001]
  • [Cites] Cancer. 1989 Jul 15;64(2):349-60 [2544249.001]
  • [Cites] Ann Surg. 2001 Jul;234(1):116-21 [11420491.001]
  • [Cites] Lancet. 2004 Oct 2-8;364(9441):1229-35 [15464183.001]
  • [Cites] Med Pediatr Oncol. 1992;20(4):360-1 [1318997.001]
  • [Cites] Eur J Cancer. 1996 May;32A(5):826-30 [9081361.001]
  • [Cites] Klin Padiatr. 2004 May-Jun;216(3):132-40 [15175957.001]
  • [Cites] Br J Cancer. 1998 Nov;78(9):1181-7 [9820177.001]
  • [Cites] Urol Clin North Am. 2000 Aug;27(3):435-42 [10985143.001]
  • [Cites] Med Pediatr Oncol. 2002 Jul;39(1):18-24 [12116074.001]
  • [Cites] Cancer Res. 2000 Aug 1;60(15):4030-2 [10945603.001]
  • [Cites] Expert Rev Anticancer Ther. 2001 Dec;1(4):555-64 [12113088.001]
  • [Cites] Br J Cancer. 1987 Sep;56(3):339-47 [2822073.001]
  • [Cites] Eur J Pediatr Surg. 1998 Apr;8(2):83-6 [9617606.001]
  • [Cites] Clin Oncol (R Coll Radiol). 1989 Nov;1(2):75-9 [2486484.001]
  • [Cites] Arch Pathol Lab Med. 2003 Oct;127(10):1280-9 [14521468.001]
  • [Cites] Cancer. 1991 Dec 1;68(11):2345-53 [1657352.001]
  • [Cites] J Clin Oncol. 1985 Apr;3(4):513-20 [2984344.001]
  • [Cites] J Urol. 2006 Jul;176(1):279-83; discussion 283-4 [16753419.001]
  • [Cites] J Clin Oncol. 1998 Dec;16(12):3744-51 [9850017.001]
  • [Cites] J Clin Oncol. 2001 Jul 1;19(13):3163-72 [11432882.001]
  • [Cites] Cancer. 1980 Apr 1;45(7):1632-6 [6245781.001]
  • [Cites] J Urol. 2003 Sep;170(3):939-42; discussion 943-4 [12913746.001]
  • [Cites] Urology. 1996 Jun;47(6):787-91 [8677564.001]
  • [Cites] Cancer. 1995 Jan 15;75(2):600-4 [7812929.001]
  • [Cites] Arch Dis Child. 1987 May;62(5):461-4 [3606177.001]
  • [Cites] Radiology. 1999 Apr;211(1):249-56 [10189480.001]
  • [Cites] Curr Opin Urol. 2005 Jul;15(4):273-6 [15928519.001]
  • [Cites] AJR Am J Roentgenol. 1999 Mar;172(3):759-63 [10063876.001]
  • [Cites] J Clin Oncol. 1993 Aug;11(8):1478-81 [8393095.001]
  • [Cites] N Engl J Med. 2006 Oct 12;355(15):1572-82 [17035650.001]
  • [Cites] Nat Clin Pract Oncol. 2005 Jun;2(6):298-304; quiz 1 p following 324 [16264987.001]
  • [Cites] Ann Oncol. 2002 Jun;13(6):819-29 [12123328.001]
  • [Cites] Semin Pediatr Surg. 2006 Feb;15(1):3-9 [16458840.001]
  • [Cites] Clin Oncol (R Coll Radiol). 1996;8(4):250-3 [8871004.001]
  • [Cites] Br J Cancer. 2004 Jul 5;91(1):37-44 [15162142.001]
  • [Cites] Cancer. 2003 Apr 15;97(8):1991-8 [12673729.001]
  • [Cites] Ann Surg. 1999 Feb;229(2):292-7 [10024113.001]
  • [Cites] Eur J Pediatr. 1993 Mar;152(3):197-200 [8383053.001]
  • [Cites] Cancer. 1999 Apr 1;85(7):1616-25 [10193955.001]
  • [Cites] J Pediatr Surg. 1996 Aug;31(8):1020-5 [8863224.001]
  • [Cites] Am J Obstet Gynecol. 2002 Oct;187(4):1070-80 [12389007.001]
  • [Cites] Cancer. 1981 May 1;47(9):2302-11 [6164480.001]
  • [Cites] Lancet. 2004 Oct 23-29;364(9444):1468-70 [15500874.001]
  • [Cites] J Pediatr Surg. 1998 Feb;33(2):165-70 [9498380.001]
  • [Cites] Am J Med Genet. 1998 Oct 2;79(4):268-73 [9781906.001]
  • [Cites] J Clin Oncol. 2004 Dec 15;22(24):4979-90 [15576413.001]
  • [Cites] J Urol. 2005 Oct;174(4 Pt 1):1172-3 [16145362.001]
  • [Cites] J Clin Oncol. 2005 Dec 20;23(36):9138-45 [16172460.001]
  • [Cites] J Clin Oncol. 1997 Jul;15(7):2631-5 [9215834.001]
  • [Cites] Hematol Oncol Clin North Am. 1995 Dec;9(6):1317-27 [8591968.001]
  • [Cites] Surg Clin North Am. 2006 Apr;86(2):469-87, xi [16580935.001]
  • [Cites] Med Pediatr Oncol. 1997 Oct;29(4):239-44 [9251727.001]
  • [Cites] BJU Int. 2006 Jul;98(1):155-9 [16831161.001]
  • [Cites] Cancer. 1976 Aug;38(2):633-46 [184912.001]
  • [Cites] Med Pediatr Oncol. 1993;21(3):172-81 [7680412.001]
  • [Cites] Med Pediatr Oncol. 1996 Feb;26(2):145-6 [8531855.001]
  • [Cites] Cancer. 1976 Aug;38(2):647-54 [184913.001]
  • [Cites] Cancer Res. 1994 May 1;54(9):2331-3 [8162576.001]
  • [Cites] Pediatr Blood Cancer. 2006 Feb;46(2):149-58 [16369924.001]
  • [Cites] J Urol. 2005 Nov;174(5):1972-5 [16217371.001]
  • [Cites] Int J Cancer. 2000 Nov 15;88(4):672-8 [11058888.001]
  • [Cites] J Clin Oncol. 2005 Oct 10;23(29):7312-21 [16129848.001]
  • [Cites] J Urol. 2005 Jun;173(6):2147 [15879875.001]
  • [Cites] Radiology. 1982 Mar;142(3):643-7 [6278535.001]
  • [Cites] Eur J Pediatr Surg. 1994 Feb;4(1):16-20 [8199126.001]
  • [Cites] J Pediatr Surg. 1992 Jul;27(7):912-5 [1322458.001]
  • [Cites] J Urol. 2004 Sep;172(3):1066-9; discussion 1069-70 [15311039.001]
  • [Cites] J Clin Oncol. 1993 Jun;11(6):1014-23 [8388918.001]
  • [Cites] Med Pediatr Oncol. 1990;18(6):441-6 [2172754.001]
  • [Cites] Br J Cancer. 2002 Nov 4;87(10):1092-8 [12402147.001]
  • [Cites] Urol Clin North Am. 2000 Aug;27(3):443-54 [10985144.001]
  • [Cites] J Clin Oncol. 2003 Sep 1;21(17 ):3269-75 [12947062.001]
  • [Cites] J Clin Oncol. 1995 Aug;13(8):1851-9 [7636528.001]
  • [Cites] Semin Urol Oncol. 1999 Feb;17(1):28-32 [10073403.001]
  • [Cites] J Clin Oncol. 2004 Jul 15;22(14):2885-90 [15254057.001]
  • (PMID = 18026723.001).
  • [ISSN] 0301-0449
  • [Journal-full-title] Pediatric radiology
  • [ISO-abbreviation] Pediatr Radiol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 119
  •  go-up   go-down


13. Hadley GP, Govender D, Landers G: Malignant solid tumours in neonates: an African perspective. Pediatr Surg Int; 2002 Dec;18(8):653-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant solid tumours in neonates: an African perspective.
  • Malignant tumours in the neonate are distinct pathologically, clinically, and therapeutically from those in older children or adults.
  • Neuroblastoma (NB) was the commonest tumour seen (11), but the soft-tissue sarcomas were the dominant group (14).
  • Chemotherapy, despite appropriate dose reduction, had significant morbidity and mortality.
  • In the absence of cytogenetic and biochemical markers, risk stratification amongst babies with NB was based upon INSS staging.
  • Patients with renal tumours, whether nephroblastoma or mesoblastic nephroma, did well.
  • [MeSH-minor] Female. Humans. Infant, Newborn. Male. Neoplasm Staging. South Africa / epidemiology. Survival Analysis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12598957.001).
  • [ISSN] 0179-0358
  • [Journal-full-title] Pediatric surgery international
  • [ISO-abbreviation] Pediatr. Surg. Int.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


14. Tröbs RB, Hänsel M, Friedrich T, Bennek J: A 23-year experience with malignant renal tumors in infancy and childhood. Eur J Pediatr Surg; 2001 Apr;11(2):92-8
MedlinePlus Health Information. consumer health - Wilms Tumor.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A 23-year experience with malignant renal tumors in infancy and childhood.
  • A retrospective analysis of 77 children treated between 1974 and 1996 was undertaken to evaluate morbidity and the evolution of therapy.
  • A Wilms' tumor (WT) was present in 73 children.
  • High-risk WT were diagnosed in 12 of 63 patients (19%) (NB with anaplasia 10, clear cell sarcoma 1, malignant rhabdoid tumor 1).
  • We observed 3 children of school age with renal carcinoma and one patient with an intrarenal neuroblastoma.
  • According to the SIOP/GPOH protocol in 1989, the regimen was switched from primary surgery to preoperative chemotherapy without biopsy in 1989 (11 pats.).
  • In 3 patients preoperative diagnosis by means of imaging failed.
  • During preoperative chemotherapy a venous occlusive disease of the liver occurred in 2 patients.
  • Preoperative chemotherapy led to an impressive tumor shrinkage in the majority of patients.
  • In our experience, reduction of tumor volume due to preoperative chemotherapy facilitates tumor removal by surgery and may prevent tumor spillage and the deleterious effects of radiation in young children.
  • Surgery without delay is necessary if the diagnosis is unclear or the tumor fails to respond to preoperative chemotherapy.
  • [MeSH-major] Kidney Neoplasms / surgery. Wilms Tumor / surgery
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Chemotherapy, Adjuvant. Child. Child, Preschool. Disease-Free Survival. Female. Humans. Infant. Male. Neoplasm Recurrence, Local / epidemiology. Neoplasm Staging. Prognosis. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11371043.001).
  • [ISSN] 0939-7248
  • [Journal-full-title] European journal of pediatric surgery : official journal of Austrian Association of Pediatric Surgery ... [et al] = Zeitschrift für Kinderchirurgie
  • [ISO-abbreviation] Eur J Pediatr Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


15. Cigolari S, Curcio C, Maiorino A, Sessa R, Cioffi A, Massimo M: Cisplatin plus vinorelbine as induction chemotherapy followed by surgery in the treatment of stage IIIB non-small cell lung cancer. Final results of a multicenter phase II study. Anticancer Res; 2003 Mar-Apr;23(2C):1803-9
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cisplatin plus vinorelbine as induction chemotherapy followed by surgery in the treatment of stage IIIB non-small cell lung cancer. Final results of a multicenter phase II study.
  • BACKGROUND: The combination of cisplatin and vinorelbine has been shown to be effective in patients with advanced non-small cell lung cancer (NSCLC).
  • Based on these data, we planned to treat patients with stage IIIB NSCLC without malignant pleural effusion and/or metastatic supraclavicular lymph nodes, in order to study the potential effectiveness of this association as neoadjuvant treatment.
  • RESULTS: A total of 82 (91.1%) cycles were administered with moderate toxicity: WHO grade (G) 2 and 3 neutropenia occurred in 20 (66.6%) patients, G 3 anaemia occurred in 4 (13.3%), G 3 nausea/vomiting in 20 (66.6%) and G 1-2 renal toxicity in 2 (6.6%).
  • CONCLUSION: The combination of cisplatin and vinorelbine is effective and safe as a neoadjuvant therapy in stage IIIB NSCLC, showing a high response rate (60%) and amenability to surgery.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Carcinoma, Non-Small-Cell Lung / surgery. Lung Neoplasms / drug therapy. Lung Neoplasms / surgery. Vinblastine / analogs & derivatives
  • [MeSH-minor] Adult. Aged. Cisplatin / administration & dosage. Cisplatin / adverse effects. Disease-Free Survival. Female. Humans. Male. Middle Aged. Neoadjuvant Therapy. Neoplasm Staging. Patient Compliance. Remission Induction

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. VINORELBINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12820462.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] Greece
  • [Chemical-registry-number] 5V9KLZ54CY / Vinblastine; Q20Q21Q62J / Cisplatin; Q6C979R91Y / vinorelbine
  •  go-up   go-down


16. Cozzi DA, Schiavetti A, Morini F, Castello MA, Cozzi F: Nephron-sparing surgery for unilateral primary renal tumor in children. J Pediatr Surg; 2001 Feb;36(2):362-5
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nephron-sparing surgery for unilateral primary renal tumor in children.
  • PURPOSE: Definition of the role of nephron-sparing surgery (NSS) in the treatment of children with primary unilateral renal tumor (URT).
  • Criteria for selection of patients eligible for NSS were at least 50% of affected kidney preservable and stage I at surgery (frozen section biopsies from regional lymph nodes, perirenal fat, and surrounding renal parenchyma).
  • Preoperative 2-drug chemotherapy was given to all patients more than 6 months of age.
  • Between 1992 and 1995, 3-drug chemotherapy was used after NSS.
  • Thereafter, following NSS, 2-drug chemotherapy was given if no microscopic residual disease was found on final histologic examination.
  • Seven children had standard histology nephroblastoma, 1 highly differentiated epithelial type nephroblastoma, 1 oncocytoma, and 1 cystic nephroma.
  • All children are alive and disease free with good functioning of the affected kidney after NSS, at a mean follow-up of 40.7 months (range, 2 to 100 months).
  • CONCLUSION: NSS should be considered in selected children with URT, especially in patients with increased risk for metachronous tumor or renal disease, and in patients with benign or low-grade malignant URT.
  • [MeSH-major] Kidney Neoplasms / surgery. Nephrectomy / methods
  • [MeSH-minor] Child. Child, Preschool. Eligibility Determination. Female. Humans. Infant. Infant, Newborn. Life Expectancy. Male. Neoplasm Staging. Postoperative Complications. Risk Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11172435.001).
  • [ISSN] 0022-3468
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Karthaus M, Metzner D, Maher G, Plahl A, Wert N: Pemetrexed + cisplatin (DDP) in patients with malignant peritoneal mesothelioma (AbM). J Clin Oncol; 2004 Jul 15;22(14_suppl):7201

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pemetrexed + cisplatin (DDP) in patients with malignant peritoneal mesothelioma (AbM).
  • : 7201 Background: Malignant pleural mesothelioma (MPM) is a rare and aggressive neoplasm of the lining of the lung.
  • Only case reports are available for treatment and outcome of AbM.
  • Pts received pemetrexed based therapy including dexamethasone prophylaxis for skin rash on day -1 to+2 additionally.
  • Study endpoints were response (RR), time to progression (TTP) and safety.
  • RESULTS: Four pts (1 AbM, 1 MPM, 2 MPM+AbM) were excluded due to renal impairment (n=1) or death prior to chemotherapy (n=3).
  • Staging revealed AbM in 11 pts, MPM in 30 pts, while 4 pts had malignant mesothelioma on both sites of the diaphragma.
  • Treatment and response data are given in the table below.
  • CONCLUSIONS: Pemetrexed in combination with DDP is a well tolerable and active regimen for advanced peritoneal malignant mesothelioma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28013854.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Camassei FD, Arancia G, Cianfriglia M, Bosman C, Francalanci P, Ravà L, Jenkner A, Donfrancesco A, Boldrini R: Nephroblastoma: multidrug-resistance P-glycoprotein expression in tumor cells and intratumoral capillary endothelial cells. Am J Clin Pathol; 2002 Mar;117(3):484-90
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nephroblastoma: multidrug-resistance P-glycoprotein expression in tumor cells and intratumoral capillary endothelial cells.
  • The development of chemoresistance in a variety of cancers seems related to overexpression of the P-glycoprotein (P-gp) drug pump.
  • Nephroblastoma, the most common malignant renal tumor of childhood, usually is responsive to treatment, and prognosis is favorable in most cases.
  • However, the disease in a subset of patients is refractory to treatment, and the disease follows an aggressive course.
  • To study P-gp expression in this tumor and its correlation with outcome, tumor samples from 93 patients were examined by immunohistochemical analysis.
  • P-gp expression was determined separately in both tumor cells and intratumoral capillary endothelium.
  • The likelihood ratio test, the Kaplan-Meier method, and the log-rank test were used to evaluate its association with clinical course, grade, stage, and administration of preoperative chemotherapy.
  • While no association of P-gp expression in tumor cells with clinical course, stage, and grade could be demonstrated, positivity in endothelial cells correlated significantly with unfavorable outcome, suggesting that chemoresistance depended on an active blood-tumor barrier.
  • Previous chemotherapy induced P-gp overexpression in tumor cells.
  • [MeSH-major] Kidney Neoplasms / chemistry. Kidney Neoplasms / pathology. P-Glycoprotein / analysis. Wilms Tumor / chemistry. Wilms Tumor / pathology
  • [MeSH-minor] Adolescent. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Capillaries. Child. Child, Preschool. Combined Modality Therapy. Dactinomycin / therapeutic use. Endothelium, Vascular / chemistry. Female. Humans. Immunohistochemistry. Infant. Male. Neoplasm Staging. Postoperative Care. Preoperative Care. Radiotherapy. Remission Induction. Retrospective Studies. Vincristine / therapeutic use

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Wilms Tumor.
  • Hazardous Substances Data Bank. DACTINOMYCIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11888090.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / P-Glycoprotein; 1CC1JFE158 / Dactinomycin; 5J49Q6B70F / Vincristine; SIOP protocol
  •  go-up   go-down


19. Wiesbauer P: [Nephrogenic tumors]. Radiologe; 2008 Oct;48(10):932-9
MedlinePlus Health Information. consumer health - Wilms Tumor.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Nephroblastomas are the most common malignant renal tumors in childhood.
  • According to the guidelines of the SIOP (Société Internationale d'Oncologie Pédiatrique) and GPOH (Gesellschaft für Pädiatrische Onkologie und Hämatologie) pre-operative chemotherapy can be started without histological confirmation and thus initial imaging studies, in particular ultrasound, play an outstanding role for diagnostic purposes.
  • [MeSH-major] Kidney Neoplasms. Wilms Tumor
  • [MeSH-minor] Adult. Age Factors. Child. Child, Preschool. Diagnosis, Differential. Female. Humans. Incidence. Kidney / pathology. Liver Neoplasms / secondary. Magnetic Resonance Imaging. Male. Neoplasm Staging. Practice Guidelines as Topic. Randomized Controlled Trials as Topic. Tomography, X-Ray Computed. Ultrasonography

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pediatr Radiol. 2006 Jul;36(7):714-7 [16770676.001]
  • [Cites] AJR Am J Roentgenol. 1997 Feb;168(2):447-51 [9016225.001]
  • [Cites] Pediatr Nephrol. 1992 Jul;6(4):365-82 [1323320.001]
  • [Cites] Pediatr Radiol. 2004 Aug;34(8):660-4 [15103425.001]
  • [Cites] Radiographics. 2000 Nov-Dec;20(6):1585-603 [11112813.001]
  • [Cites] Pediatr Radiol. 2001 Oct;31(10):732-6 [11685444.001]
  • [Cites] J Pediatr Surg. 2004 Apr;39(4):522-5 [15065020.001]
  • [Cites] Pediatr Radiol. 2000 Aug;30(8):533-7; discussion 537-9 [10993537.001]
  • [Cites] Eur Radiol. 2003 Dec;13 Suppl 4:L116-29 [15018176.001]
  • [Cites] Cancer Imaging. 2007 Mar 05;7:41-51 [17339140.001]
  • [Cites] Pediatr Radiol. 1997 Mar;27(3):285 [9126596.001]
  • [Cites] Pediatr Radiol. 2003 Sep;33(9):594-7 [12856167.001]
  • [Cites] Pediatr Radiol. 1994;24(3):213-5 [7936803.001]
  • [Cites] Acta Radiol. 1995 May;36(3):254-60 [7742117.001]
  • [Cites] Eur J Pediatr Surg. 2001 Apr;11(2):92-8 [11371043.001]
  • [Cites] Pediatr Radiol. 2004 Feb;34(2):152-5 [14530886.001]
  • [Cites] Br J Cancer. 1980 Jun;41(6):875-9 [6252920.001]
  • [Cites] Radiographics. 1995 May;15(3):653-69 [7624570.001]
  • [Cites] Urol Clin North Am. 2000 Aug;27(3):463-9, ix [10985146.001]
  • [Cites] Eur J Pediatr Surg. 1996 Jun;6(3):186-8 [8817218.001]
  • [Cites] Pediatr Radiol. 2003 Feb;33(2):123-8 [12557069.001]
  • [Cites] Urologe A. 2005 Feb;44(2):155-61 [15672236.001]
  • [Cites] Clin Radiol. 1999 May;54(5):321-7 [10362240.001]
  • [Cites] Radiol Clin North Am. 1997 Nov;35(6):1391-413 [9374996.001]
  • [Cites] Pediatr Radiol. 1998 Jun;28(6):435-43 [9634458.001]
  • [Cites] Magn Reson Imaging Clin N Am. 2002 May;10(2):275-302 [12424947.001]
  • (PMID = 18854965.001).
  • [ISSN] 0033-832X
  • [Journal-full-title] Der Radiologe
  • [ISO-abbreviation] Radiologe
  • [Language] ger
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


20. Schenk JP, Graf N, Günther P, Ley S, Göppl M, Kulozik A, Rohrschneider WK, Tröger J: Role of MRI in the management of patients with nephroblastoma. Eur Radiol; 2008 Apr;18(4):683-91
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Magnetic resonance imaging (MRI) presents the main diagnostic tool for differentiation and staging of renal tumors in childhood.
  • Nephroblastoma is the most common malignant tumor in children.
  • Radiological findings play an important role in therapy study trials of SIOP (International Society of Pediatric Oncology), especially for indicating preoperative chemotherapy.
  • In the past few years MRI has gained great importance in imaging of nephroblastoma and has replaced computed tomography (CT).
  • The aim of this review is to present the diagnostic possibilities of MRI in relation to the requirements of therapy studies.
  • For nephroblastoma, MRI provides important information about tumor extent and distant metastasis.
  • A special focus of MRI in distant staging is venous extent of the tumor into the inferior vena cava.
  • In addition, MRI has an important role in monitoring chemotherapy and in preoperative planning by volume rendering and three-dimensional postprocessing.
  • [MeSH-major] Kidney Neoplasms / diagnosis. Magnetic Resonance Imaging / methods. Wilms Tumor / diagnosis
  • [MeSH-minor] Child. Contrast Media. Humans. Image Interpretation, Computer-Assisted. Imaging, Three-Dimensional. Neoplasm Staging

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • MedlinePlus Health Information. consumer health - Wilms Tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Am Coll Surg. 2001 Jan;192(1):63-8; quiz 146 [11192924.001]
  • [Cites] Rofo. 2006 Jan;178(1):38-45 [16392056.001]
  • [Cites] Pediatr Radiol. 1994;24(2):85-7 [8078728.001]
  • [Cites] Pediatr Radiol. 2005 Aug;35(8):766-73 [15864576.001]
  • [Cites] Radiographics. 2004 Sep-Oct;24(5):1317-30 [15371611.001]
  • [Cites] Pediatr Radiol. 2004 Aug;34(8):660-4 [15103425.001]
  • [Cites] Radiologe. 2005 Dec;45(12 ):1112-23 [16151729.001]
  • [Cites] AJR Am J Roentgenol. 2001 Jul;177(1):229-36 [11418435.001]
  • [Cites] Langenbecks Arch Chir Suppl Kongressbd. 1996;113:1078-83 [9101785.001]
  • [Cites] Klin Padiatr. 2004 May-Jun;216(3):132-40 [15175957.001]
  • [Cites] Med Pediatr Oncol. 2000 Mar;34(3):183-90 [10696124.001]
  • [Cites] Radiologe. 2001 May;41(5):418-26 [11405103.001]
  • [Cites] J Urol. 2003 Sep;170(3):939-42; discussion 943-4 [12913746.001]
  • [Cites] Pediatr Pathol. 1990;10(1-2):1-36 [2156243.001]
  • [Cites] Radiographics. 1998 Jul-Aug;18(4):947-68 [9672980.001]
  • [Cites] Eur J Pediatr Surg. 2004 Oct;14(5):316-21 [15543480.001]
  • [Cites] Rofo. 2004 Oct;176(10):1447-52 [15383976.001]
  • [Cites] J Pediatr Surg. 1998 Feb;33(2):165-70 [9498380.001]
  • [Cites] Rofo. 2005 Oct;177(10):1373-9 [16170706.001]
  • [Cites] Pediatr Radiol. 2006 Oct;36(10):1075-81 [16896692.001]
  • [Cites] J Pediatr Surg. 2005 Feb;40(2):364-70 [15750930.001]
  • [Cites] Radiology. 1993 Aug;188(2):517-21 [8392214.001]
  • [Cites] Rofo. 2005 Jun;177(6):800-4 [15902628.001]
  • [Cites] Vestn Rentgenol Radiol. 2001 Nov-Dec;(6):29-43 [11858031.001]
  • [Cites] Pediatr Radiol. 1998 Jun;28(6):435-43 [9634458.001]
  • [Cites] Br J Urol. 1996 Nov;78(5):772-6 [8976777.001]
  • [Cites] Magn Reson Imaging Clin N Am. 2002 May;10(2):275-302 [12424947.001]
  • [Cites] Urol Clin North Am. 2000 Aug;27(3):443-54 [10985144.001]
  • [Cites] J Pediatr Surg. 1991 Jan;26(1):64-7 [1848614.001]
  • (PMID = 18193429.001).
  • [ISSN] 0938-7994
  • [Journal-full-title] European radiology
  • [ISO-abbreviation] Eur Radiol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Contrast Media
  • [Number-of-references] 30
  •  go-up   go-down


21. Suita S, Kinoshita Y, Tajiri T, Hara T, Tsuneyoshi M, Mizote H, Inada H, Takamatsu H, Kawano Y, Inomata Y, Nagasaki A, Ono Y, Handa N, Okamura J, Ishii E, Kawakami K, Committee for pediatric solid malignant tumors in the Kyushu area: Clinical characteristics and outcome of Wilms tumors with a favorable histology in Japan: a report from the Study Group for Pediatric Solid Malignant Tumors in the Kyushu Area, Japan. J Pediatr Surg; 2006 Sep;41(9):1501-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical characteristics and outcome of Wilms tumors with a favorable histology in Japan: a report from the Study Group for Pediatric Solid Malignant Tumors in the Kyushu Area, Japan.
  • BACKGROUND/PURPOSE: Since 1996, the standard treatment of Wilms tumors in Japan has been based on the regimen of the Japanese Wilms Tumor Study.
  • This study aims to assess the clinical characteristics of patients with Wilms tumor with a favorable histology from a retrospective standpoint in the Kyushu area in Japan and, furthermore, to analyze the historical changes of clinical features and outcome from the 1980s to the 1990s.
  • All stage V cases in group B undewent a bilateral tumor biopsy instead of a radical nephrectomy as the initial operation.
  • The present study suggested that in the early-stage cases, an initially complete resection followed by standard postoperative chemotherapy substantially improved the outcome of the patients in group B.
  • In the stage V cases, the performance of renal salvage surgery may have positively contributed to the improvement in the outcome in group B.
  • In the future, an improved efficacy of the treatments for Wilms tumors based on the standard protocol established by the Japanese Wilms Tumor Study in 1996 is expected in Japan.
  • [MeSH-major] Kidney Neoplasms / mortality. Wilms Tumor / mortality
  • [MeSH-minor] Child, Preschool. Female. Humans. Infant. Infant, Newborn. Japan. Male. Neoplasm Staging. Nephrectomy. Retrospective Studies. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Wilms Tumor.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16952581.001).
  • [ISSN] 1531-5037
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Schenk JP, Günther P, Schrader C, Ley S, Furtwängler R, Leuschner I, Edelhäuser M, Graf N, Tröger J: [Childhood kidney tumors -- the relevance of imaging]. Radiologe; 2005 Dec;45(12):1112-23
MedlinePlus Health Information. consumer health - Wilms Tumor.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Childhood kidney tumors -- the relevance of imaging].
  • Kidney tumors represent 6.2% of malignant tumors in children.
  • History, clinical course and radiological findings are necessary elements in the differential diagnosis of the different renal tumors.
  • In the case of nephroblastoma, chemotherapy is based solely on the radiological diagnosis without prior histology.
  • In therapy-optimizing studies of the Society of Pediatric Oncology and Hematology, preoperative chemotherapy is performed.
  • Therapy monitoring is performed in the course of and after preoperative chemotherapy to verify tumor response.
  • Radiological staging plays a significant role in deciding on further treatment and in operative planning.
  • In summary, diagnostic imaging in renal tumors in children plays a role in differential diagnosis, staging, monitoring of therapy, and surgical planning.
  • [MeSH-major] Kidney Neoplasms / diagnosis. Magnetic Resonance Imaging. Tomography, X-Ray Computed. Wilms Tumor / diagnosis
  • [MeSH-minor] Abnormalities, Multiple / diagnosis. Adolescent. Child. Child, Preschool. Diagnosis, Differential. Female. Humans. Infant. Infant, Newborn. Kidney / pathology. Kidney Diseases / diagnosis. Male. Neoplasm Staging. Ultrasonography

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Am Coll Surg. 2001 Jan;192(1):63-8; quiz 146 [11192924.001]
  • [Cites] AJR Am J Roentgenol. 1997 Feb;168(2):447-51 [9016225.001]
  • [Cites] Int J Urol. 2004 Jan;11(1):50-2 [14678186.001]
  • [Cites] Pediatr Radiol. 1994;24(2):85-7 [8078728.001]
  • [Cites] Pediatr Radiol. 2004 Aug;34(8):660-4 [15103425.001]
  • [Cites] Urol Radiol. 1992;14 (4):241-51 [1335188.001]
  • [Cites] Cancer. 1978 Oct;42(4):1922-8 [213188.001]
  • [Cites] J Urol. 1998 Jul;160(1):141-5 [9628635.001]
  • [Cites] Urologe A. 2003 Mar;42(3):W391-407; quiz W408-9 [12723542.001]
  • [Cites] Langenbecks Arch Chir Suppl Kongressbd. 1996;113:1078-83 [9101785.001]
  • [Cites] Am J Surg Pathol. 1989 Jun;13(6):439-58 [2543225.001]
  • [Cites] Klin Padiatr. 2004 May-Jun;216(3):132-40 [15175957.001]
  • [Cites] Hum Pathol. 1983 Jun;14(6):481-92 [6303938.001]
  • [Cites] Radiographics. 2000 Nov-Dec;20(6):1585-603 [11112813.001]
  • [Cites] Urologe A. 2004 Apr;43(4):421-8 [15042291.001]
  • [Cites] Med Pediatr Oncol. 2000 Mar;34(3):183-90 [10696124.001]
  • [Cites] Radiologe. 2001 May;41(5):418-26 [11405103.001]
  • [Cites] Pediatr Radiol. 1995 Nov;25 Suppl 1:S73-5 [8577561.001]
  • [Cites] Radiology. 1991 Sep;180(3):715-7 [1871282.001]
  • [Cites] J Pediatr. 1987 Jul;111(1):64-70 [3037055.001]
  • [Cites] Rofo. 2004 Jul;176(7):965-71 [15237338.001]
  • [Cites] Australas Radiol. 1999 Nov;43(4):532-4 [10901975.001]
  • [Cites] J Urol. 2003 Sep;170(3):939-42; discussion 943-4 [12913746.001]
  • [Cites] AJR Am J Roentgenol. 1980 Aug;135(2):381-4 [6250384.001]
  • [Cites] Radiographics. 1998 Jul-Aug;18(4):947-68 [9672980.001]
  • [Cites] Eur J Pediatr Surg. 2004 Oct;14(5):316-21 [15543480.001]
  • [Cites] Chirurg. 1996 Jun;67(6):584-92 [8767086.001]
  • [Cites] Rofo. 2004 Oct;176(10):1447-52 [15383976.001]
  • [Cites] Br J Cancer. 1980 Jun;41(6):875-9 [6252920.001]
  • [Cites] Histopathology. 1998 Apr;32(4):293-309 [9602325.001]
  • [Cites] Pediatr Radiol. 1999 Feb;29(2):100-3 [9933328.001]
  • [Cites] J Pediatr Surg. 2000 May;35(5):677-9 [10813321.001]
  • [Cites] J Pediatr Surg. 1998 Feb;33(2):165-70 [9498380.001]
  • [Cites] Rofo. 2005 Oct;177(10):1373-9 [16170706.001]
  • [Cites] Radiology. 1995 Apr;195(1):83-5 [7892499.001]
  • [Cites] Radiographics. 2000 Jan-Feb;20(1):215-43 [10682782.001]
  • [Cites] J Pediatr Surg. 2005 Feb;40(2):364-70 [15750930.001]
  • [Cites] Urologe A. 2002 Nov;41(6):577-82 [12524945.001]
  • [Cites] Pediatr Radiol. 2002 Nov;32(11):829-31 [12389112.001]
  • [Cites] Pediatr Radiol. 2003 Feb;33(2):123-8 [12557069.001]
  • [Cites] Radiology. 1993 Aug;188(2):517-21 [8392214.001]
  • [Cites] Pediatr Pathol Lab Med. 1995 Sep-Oct;15(5):745-62 [8597860.001]
  • [Cites] Radiology. 1988 Jan;166(1 Pt 1):153-6 [2827229.001]
  • [Cites] Urologe A. 2005 Feb;44(2):155-61 [15672236.001]
  • [Cites] Vestn Rentgenol Radiol. 2001 Nov-Dec;(6):29-43 [11858031.001]
  • [Cites] J Pediatr Surg. 1995 Jun;30(6):856-9 [7666322.001]
  • [Cites] Radiol Clin North Am. 1997 Nov;35(6):1391-413 [9374996.001]
  • [Cites] Pediatr Radiol. 1998 Jun;28(6):435-43 [9634458.001]
  • [Cites] Perspect Pediatr Pathol. 1976;3:185-223 [184429.001]
  • [Cites] Br J Urol. 1996 Nov;78(5):772-6 [8976777.001]
  • [Cites] J Pediatr. 1998 Mar;132(3 Pt 1):377-9 [9544882.001]
  • [Cites] J Pediatr Surg. 1991 Jan;26(1):64-7 [1848614.001]
  • (PMID = 16151729.001).
  • [ISSN] 0033-832X
  • [Journal-full-title] Der Radiologe
  • [ISO-abbreviation] Radiologe
  • [Language] ger
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


23. Leath CA 3rd, Huh WK, Conner M, Barnes MN 3rd: Primary extrarenal rhabdoid tumor of the ovary. A case report. J Reprod Med; 2003 Apr;48(4):283-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary extrarenal rhabdoid tumor of the ovary. A case report.
  • BACKGROUND: Malignant rhabdoid tumors are rare, aggressive neoplasms that consist of both renal and extrarenal subtypes.
  • CASE: An 18-year-old, Caucasian woman was diagnosed with a pure primary extrarenal rhabdoid tumor of the ovary following diagnostic laparoscopy for pelvic pain.
  • The tumor exhibited rapid growth, failed to respond to chemotherapy and led rapidly to death.
  • CONCLUSION: Although no other reports on primary ovarian extrarenal rhabdoid tumor have been published, the aggressive behavior of the tumor in this patient was similar to that seen in patients with metastatic disease.
  • [MeSH-major] Ovarian Neoplasms / pathology. Rhabdoid Tumor / pathology
  • [MeSH-minor] Adolescent. Biopsy, Needle. Chemotherapy, Adjuvant. Combined Modality Therapy. Disease Progression. Fatal Outcome. Female. Humans. Immunohistochemistry. Laparoscopy / methods. Neoplasm Staging. Pelvic Pain / diagnosis. Pelvic Pain / etiology. Rare Diseases

  • Genetic Alliance. consumer health - Rhabdoid tumor.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12746993.001).
  • [ISSN] 0024-7758
  • [Journal-full-title] The Journal of reproductive medicine
  • [ISO-abbreviation] J Reprod Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


24. vom Dorp F, Krege S, Rübben H: [Inductive systemic therapy of urological tumors with curative intent]. Urologe A; 2007 Oct;46(10):1400-3
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Inductive systemic therapy of urological tumors with curative intent].
  • [Transliterated title] Induktive Systemtherapie mit kurativer Zielsetzung urologischer Tumoren.
  • Up to now systemic therapy with curative intent is possible in only a few tumors.
  • Concerning advanced malignant tumors in urology only testicular cancer can be cured.
  • In metastatic urothelial cancer of the bladder this might be possible in single cases.
  • In advanced renal cell carcinoma a recent group of new substances, so-called target-specific substances, have gained attention.
  • The amazing results in testicular cancer were possible by consistent performance of clinical trials.
  • The success in treatment also is an example for interdisciplinarity.
  • Especially in advanced stages treatment consists of two components, chemotherapy, correctly performed concerning dose and interval, followed by complete residual tumor resection.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Neoadjuvant Therapy
  • [MeSH-minor] Biomarkers, Tumor / blood. Bleomycin / administration & dosage. Bleomycin / adverse effects. Cisplatin / administration & dosage. Cisplatin / adverse effects. Combined Modality Therapy. Drug Delivery Systems. Etoposide / administration & dosage. Etoposide / adverse effects. Humans. Ifosfamide / administration & dosage. Ifosfamide / adverse effects. Lymph Node Excision. Male. Neoplasm Staging. Neoplasms, Germ Cell and Embryonal / drug therapy. Neoplasms, Germ Cell and Embryonal / mortality. Neoplasms, Germ Cell and Embryonal / pathology. Neoplasms, Germ Cell and Embryonal / surgery. Orchiectomy. Prognosis. Seminoma / drug therapy. Seminoma / mortality. Seminoma / pathology. Seminoma / surgery. Survival Rate. Taxoids / administration & dosage. Taxoids / adverse effects. Testicular Neoplasms / drug therapy. Testicular Neoplasms / mortality. Testicular Neoplasms / pathology. Testicular Neoplasms / surgery. Treatment Outcome. Vinblastine / administration & dosage. Vinblastine / adverse effects

  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1997 Feb;15(2):594-603 [9053482.001]
  • [Cites] Eur Urol. 2007 Mar;51(3):739-46; discussion 747-8 [17084512.001]
  • [Cites] J Urol. 2003 Jun;169(6):2113-7 [12771730.001]
  • [Cites] J Clin Oncol. 2007 Jul 1;25(19):2778-84 [17602082.001]
  • [Cites] J Clin Oncol. 1997 May;15(5):1837-43 [9164193.001]
  • [Cites] N Engl J Med. 2007 Jan 11;356(2):115-24 [17215529.001]
  • [Cites] J Clin Oncol. 2006 Jan 20;24(3):467-75 [16421423.001]
  • [Cites] Br J Cancer. 2005 Jul 25;93(2):200-7 [15999104.001]
  • [Cites] J Natl Cancer Inst. 2007 Apr 4;99(7):533-44 [17405998.001]
  • [Cites] N Engl J Med. 2007 Jan 11;356(2):125-34 [17215530.001]
  • [Cites] Ann Oncol. 2002 Apr;13(4):599-605 [12056711.001]
  • [Cites] J Clin Oncol. 2004 Mar 15;22(6):1034-9 [15020605.001]
  • [Cites] J Clin Oncol. 2007 Jan 20;25(3):247-56 [17235042.001]
  • [Cites] Semin Oncol. 1998 Apr;25(2):174-85 [9562450.001]
  • [Cites] J Urol. 2004 Jan;171(1):145-8 [14665863.001]
  • [Cites] Cancer. 1989 Dec 15;64(12):2448-58 [2819654.001]
  • [Cites] J Clin Oncol. 1997 Apr;15(4):1427-31 [9193335.001]
  • [Cites] Br J Cancer. 1998 Sep;78(6):828-32 [9743309.001]
  • [Cites] J Clin Oncol. 2000 Sep;18(17):3068-77 [11001674.001]
  • [Cites] J Clin Oncol. 2000 Mar;18(6):1173-80 [10715285.001]
  • [Cites] J Cancer Res Clin Oncol. 2005 Apr;131(4):255-60 [15627215.001]
  • [Cites] J Clin Oncol. 2000 Jun;18(12):2413-8 [10856101.001]
  • (PMID = 17874061.001).
  • [ISSN] 0340-2592
  • [Journal-full-title] Der Urologe. Ausg. A
  • [ISO-abbreviation] Urologe A
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Taxoids; 11056-06-7 / Bleomycin; 5V9KLZ54CY / Vinblastine; 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin; UM20QQM95Y / Ifosfamide; BEP protocol; ICE protocol 1; TIP regimen; VeIP protocol
  •  go-up   go-down


25. Thijssens K, Vaneerdeweg W, Schrijvers D, Eyskens E, Van Oosterom A: Retroperitoneal lymph node dissection as adjuvant therapy in the treatment of non-seminomatous testicular cancer. Acta Chir Belg; 2003 Nov-Dec;103(6):599-602
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Retroperitoneal lymph node dissection as adjuvant therapy in the treatment of non-seminomatous testicular cancer.
  • OBJECTIVE: To assess the results of retroperitoneal lymph node dissection (RPLND) of residual masses in patients with disseminated non-seminomatous germ cell tumour treated with cisplatin-based chemotherapy, both in terms of extension of surgery, morbidity and survival.
  • In patients with non-seminomatous testicular cancer more than stage I, the 'wait and see' strategy changed and patients were treated with chemotherapy.
  • Patients were assessed at the end of chemotherapy and if a residual masses persisted, a RPLND was performed.
  • RESULTS: Sixty patients had a non-seminomatous germ cell tumor of the testis and were analysed.
  • Forty-seven patients were treated with cisplatin-based chemotherapy.
  • Fifteen patients underwent RPLND above the level of the renal trunk.
  • In two patients malignant cells or fibrotic tissue were found above the renal trunk and bilateral.
  • In five patients viable tumour cells were found in the region below the renal trunk.
  • Sixteen patients underwent RPLND below the level of the renal trunk, of which nine had a unilateral resection, containing viable tumour in two patients.
  • The survival of the patients treated with a RPLND was 97% and in the whole group of patients with a non-seminomatous testicular cancer 98%.
  • CONCLUSION: RPLND has a place in the treatment of patients with non-seminomatous testicular cancer after chemotherapy in case of residual masses.
  • In a limited number of patients there was a need of resection of adherent organs when a resection above the renal trunk was performed.
  • [MeSH-minor] Adult. Belgium. Chemotherapy, Adjuvant. Cohort Studies. Disease-Free Survival. Follow-Up Studies. Humans. Lymph Nodes / pathology. Lymph Nodes / surgery. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. Retrospective Studies. Risk Assessment. Sensitivity and Specificity. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Testicular cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14743567.001).
  • [ISSN] 0001-5458
  • [Journal-full-title] Acta chirurgica Belgica
  • [ISO-abbreviation] Acta Chir. Belg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Belgium
  •  go-up   go-down


26. Volkmer BG, Seidl-Schlick EM, Bach D, Romics I, Kleinschmidt K: Cyclophosphamide is contraindicated in patients with a history of transitional cell carcinoma. Clin Rheumatol; 2005 Aug;24(4):319-23
Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cyclophosphamide is a urotoxic agent that increases the incidence of malignant neoplasms of the urinary tract.
  • The aim of this study was to evaluate the long-term impact of cyclophosphamide on patients with a history of superficial bladder cancer.
  • Tumor staging, grading, and size were equally distributed in both groups.
  • No significant difference could be observed regarding the 10-year overall survival rate (group A: 59%, group B: 58%), the 10-year tumor-specific survival rate (89 vs 94%), and the 10-year progression-free survival rate (85 vs 97%).
  • Whereas there were no recurrences in the upper urinary tract among the patients of group B, 2 of the 22 patients from group A developed cancer of the renal pelvis.
  • In patients with a history of superficial bladder cancer, a single dose of cyclophosphamide poses a significantly increased risk of tumor recurrence in the lower and in the upper urinary tract as well.
  • [MeSH-major] Carcinoma, Transitional Cell / drug therapy. Cyclophosphamide / adverse effects. Neoplasm Recurrence, Local / chemically induced. Urinary Bladder Neoplasms / drug therapy
  • [MeSH-minor] Administration, Intravesical. Adult. Aged. Aged, 80 and over. Chemotherapy, Adjuvant. Cystectomy / methods. Cystoscopy. Female. Humans. Incidence. Infusions, Intravenous. Male. Middle Aged. Mycobacterium bovis. Neoplasm Staging. Probability. Prognosis. Risk Assessment. Survival Analysis. Treatment Outcome. Ultrasonography

  • Genetic Alliance. consumer health - Transitional cell carcinoma.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Urol Clin North Am. 1984 Nov;11(4):557-66 [6506370.001]
  • [Cites] Br Med J. 1971 Jul 17;3(5767):182 [5109123.001]
  • [Cites] J Rheumatol. 1999 Aug;26(8):1705-14 [10451066.001]
  • [Cites] Urology. 1980 Aug;16(2):145-8 [6250267.001]
  • [Cites] Urol Int. 1993;51(1):49-53 [8333092.001]
  • [Cites] Ann Intern Med. 1996 Mar 1;124(5):477-84 [8602705.001]
  • [Cites] J Urol. 1981 Mar;125(3):424-6 [7206101.001]
  • [Cites] N Engl J Med. 1988 Sep 29;319(13):871 [3412418.001]
  • [Cites] N Engl J Med. 1988 Apr 21;318(16):1028-32 [3352696.001]
  • [Cites] Urologe A. 1986 Jan;25(1):51-4 [3962045.001]
  • [Cites] Arthritis Rheum. 1995 Aug;38(8):1120-7 [7639809.001]
  • [Cites] J Urol. 1988 Nov;140(5):1009-11 [3050150.001]
  • [Cites] Urology. 1978 May;11(5):437-47 [675898.001]
  • [Cites] Arch Pathol Lab Med. 1982 May;106(5):247-9 [6896137.001]
  • [Cites] J Urol. 1983 Jan;129(1):29-32 [6827684.001]
  • [Cites] J Urol. 1996 Dec;156(6):1931-3 [8911359.001]
  • [Cites] Cancer Res. 1977 Aug;37(8 Pt 2):2918-29 [406041.001]
  • (PMID = 16034647.001).
  • [ISSN] 0770-3198
  • [Journal-full-title] Clinical rheumatology
  • [ISO-abbreviation] Clin. Rheumatol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 8N3DW7272P / Cyclophosphamide
  •  go-up   go-down


27. Basta-Jovanović G, Radonjic V, Stolic I, Nenadovic M, Brasanac D, Jovanovic D, Radojevic-Skodric S: Significance of proto-oncogene Bcl-X(S/L) expression in Wilms tumor. Ren Fail; 2005;27(1):13-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Significance of proto-oncogene Bcl-X(S/L) expression in Wilms tumor.
  • The rate of apoptosis varies in malignant tumors, and it can be involved in diminishing tumor size.
  • In human renal diseases, such as the experimental model of acute renal failure, and many tumors, including Wilms' tumor, the expression of antiapoptotic members of Bcl-2 family is increased, while the expression of proapoptotic members is low.
  • AIM: The aim of our study was to investigate Bcl-X(S/L) protein expression in Wilms' tumor, to compare it with the expression in normal renal tissue, as well as to see if there is a correlation between Bcl-X(S/L) expression in Wilms' tumor with tumor stage, histological type, prognostic group, or response to preoperative chemotherapy.
  • MATERIALS AND METHODS: Twenty-eight cases of Wilms' tumor (two cases with metastasis) and two samples of normal kidney tissue were studied using streptavidin-biotin-complex technique.
  • RESULTS: The expression of Bcl-X(S/L) was observed in the majority of cases (60.7%), more often in the blastemal than in the epithelial component of Wilms' tumor: 60.7% and 28.6%, respectively (p=0.02).
  • There was a statistically significant inverse relationship between Bcl-X(S/L) expression and tumor stage (p=0.015).
  • Expression of Bcl-X(S/L) was detected in various histological types of Wilms' tumor, but there was no statistically significant association (p=0.82) except in cases with diffuse anaplasia (p=0.012), which were always negative.
  • No Bcl-X(S/L) immunostaining was observed in two cases of metastasis or in one case of bilateral Wilms' tumor.
  • CONCLUSION: Our results suggest that the expression of Bcl-X(S/L) protein is associated with prognostic group, tumor stage, and presence of anaplasia.
  • [MeSH-major] Kidney / pathology. Proto-Oncogene Proteins c-bcl-2 / biosynthesis. Wilms Tumor / metabolism
  • [MeSH-minor] Anaplasia. Antineoplastic Agents / therapeutic use. Apoptosis. Child. Child, Preschool. Female. Humans. Infant. Male. Neoadjuvant Therapy. Neoplasm Staging. Prognosis. bcl-X Protein

  • MedlinePlus Health Information. consumer health - Wilms Tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15717629.001).
  • [ISSN] 0886-022X
  • [Journal-full-title] Renal failure
  • [ISO-abbreviation] Ren Fail
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / BCL2L1 protein, human; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / bcl-X Protein
  •  go-up   go-down


28. Engin G, Asoglu O, Kapran Y, Mert G: A gastrointestinal stromal tumor with mesenteric and retroperitoneal invasion. World J Surg Oncol; 2007;5:121
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A gastrointestinal stromal tumor with mesenteric and retroperitoneal invasion.
  • In this report we present a case of gastrointestinal stromal tumors with mesenteric and retroperitoneal invasion, describe and discuss its computed tomography findings.
  • During physical examination, significant distention and multiple palpable tumor masses were identified on the abdomen.
  • Abdominal computed tomography showed multiple, well-defined, soft tissue masses with homogenous and heterogeneous pattern, in the mesenteric and retroperitoneal areas.
  • Unlike specific features of gastrointestinal stromal tumor, renal obstruction and atypical central calcification without chemotherapy that has not been yet described were seen in this case.
  • Computed tomography did not reveal liver metastases and/or the lymph nodes with pathological size.
  • Ultrasonography-guided true-cut biopsy was made, histopathologic and immunohistochemical analyses demonstrated stromal tumor which, C-KIT (+).
  • Postoperative histopathological analyses revealed lower grade malignant GISTs.
  • CONCLUSION: When intraabdominal, multiple, large (>5 cm), well-circumscribed, homogenous or heterogeneous mass lesions without ascites, omental caking and lymph nodes metastases were seen, gastrointestinal stromal tumors should be considered in the differential diagnosis.
  • [MeSH-major] Gastrointestinal Stromal Tumors / pathology. Neoplasm Invasiveness / pathology. Peritoneal Neoplasms / pathology. Retroperitoneal Neoplasms / pathology
  • [MeSH-minor] Abdominal Pain / diagnosis. Abdominal Pain / etiology. Biopsy, Needle. Follow-Up Studies. Humans. Immunohistochemistry. Laparotomy. Male. Mesentery. Middle Aged. Neoplasm Staging. Risk Assessment. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Control. 2005 Apr;12(2):111-5 [15855894.001]
  • [Cites] Ann Oncol. 2005 Apr;16(4):566-78 [15781488.001]
  • [Cites] Pol J Pathol. 2005;56(2):51-61 [16092666.001]
  • [Cites] Eur J Surg Oncol. 2006 Apr;32(3):310-4 [16414236.001]
  • [Cites] Radiographics. 2006 Mar-Apr;26(2):481-95 [16549611.001]
  • [Cites] World J Gastroenterol. 2007 Apr 14;13(14):2077-82 [17465451.001]
  • [Cites] Am J Surg Pathol. 2000 Feb;24(2):211-22 [10680889.001]
  • [Cites] Mod Pathol. 2000 May;13(5):577-85 [10824931.001]
  • [Cites] Mod Pathol. 2000 Oct;13(10):1134-42 [11048809.001]
  • [Cites] Am J Surg Pathol. 2001 Sep;25(9):1121-33 [11688571.001]
  • [Cites] Gastrointest Endosc. 2002 Jan;55(1):37-43 [11756912.001]
  • [Cites] Radiology. 2003 Feb;226(2):527-32 [12563150.001]
  • [Cites] Am J Clin Pathol. 2003 May;119(5):703-8 [12760289.001]
  • [Cites] Eur Radiol. 2003 Jul;13(7):1669-78 [12835984.001]
  • [Cites] Br J Surg. 2003 Oct;90(10):1178-86 [14515284.001]
  • [Cites] World J Gastroenterol. 2004 Aug 15;10(16):2417-8 [15285033.001]
  • [Cites] Eur Radiol. 2004 Oct;14(10):1926-9 [15300393.001]
  • [Cites] Hum Pathol. 1992 Jul;23(7):762-7 [1612575.001]
  • [Cites] Am J Surg Pathol. 1993 Jun;17(6):588-94 [8333557.001]
  • [Cites] Mod Pathol. 1997 Mar;10(3):200-9 [9071727.001]
  • [Cites] Am J Surg Pathol. 1997 Apr;21(4):407-16 [9130987.001]
  • [Cites] Ann Surg. 1998 Sep;228(3):355-65 [9742918.001]
  • [Cites] Am J Surg Pathol. 1999 Jan;23(1):82-7 [9888707.001]
  • [Cites] Am J Surg Pathol. 1999 Aug;23(8):937-45 [10435564.001]
  • [Cites] AJR Am J Roentgenol. 2005 Mar;184(3):803-11 [15728601.001]
  • [Cites] Eur Radiol. 2005 Jul;15(7):1407-14 [15761716.001]
  • (PMID = 17958889.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2164961
  •  go-up   go-down


29. van den Hoek J, de Krijger R, van de Ven K, Lequin M, van den Heuvel-Eibrink MM: Cystic nephroma, cystic partially differentiated nephroblastoma and cystic Wilms' tumor in children: a spectrum with therapeutic dilemmas. Urol Int; 2009;82(1):65-70
MedlinePlus Health Information. consumer health - Wilms Tumor.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cystic nephroma, cystic partially differentiated nephroblastoma and cystic Wilms' tumor in children: a spectrum with therapeutic dilemmas.
  • BACKGROUND: Cystic renal tumors are a diagnostic and therapeutic challenge.
  • Cystic nephroma (CN), cystic partially differentiated nephroblastoma (CPDN) and cystic Wilms' tumor (CWT) are a spectrum with CN at the benign end, CWT at the malignant end and CPDN in the intermediate position.
  • International Society of Pediatric Oncology (SIOP) protocols for Wilms' tumor (WT) advocate preoperative chemotherapy, which may be unnecessary and potentially harmful in CN and in stage 1 CPDN.
  • There are difficulties in differentiating the three types using imaging techniques.
  • Therefore, controversies exist regarding the optimal treatment.
  • METHODS: We describe 6 children, who each had a postoperative diagnosis of CN, CPDN or CWT, and we retrospectively evaluate the treatment strategies.
  • RESULTS: The three types cannot be differentiated using imaging techniques, although the presence of solid components in the tumor is indicative of WT.
  • CONCLUSIONS: Surgery as first-line therapy should be seriously considered in children who have a cystic renal tumor, but further collaborative studies are needed since the distinction line between CPDN and CWT is not always clear.
  • [MeSH-major] Kidney Diseases, Cystic / surgery. Kidney Neoplasms / surgery. Nephrectomy. Wilms Tumor / surgery
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols. Biopsy. Cell Differentiation. Chemotherapy, Adjuvant. Child, Preschool. Diagnosis, Differential. Disease Progression. Female. Humans. Infant. Magnetic Resonance Imaging. Male. Neoadjuvant Therapy. Neoplasm Staging. Retrospective Studies. Tomography, X-Ray Computed. Treatment Outcome. Ultrasonography

  • Genetic Alliance. consumer health - Wilms' tumor.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Kidney Cysts.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2009 S. Karger AG, Basel.
  • (PMID = 19172100.001).
  • [ISSN] 1423-0399
  • [Journal-full-title] Urologia internationalis
  • [ISO-abbreviation] Urol. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


30. Yashi M, Nukui A, Kurokawa S, Ochi M, Ishikawa S, Goto K, Kobayashi Y, Muraishi O, Tokue A: Elevated serum progastrin-releasing peptide (31-98) level is a predictor of short response duration after hormonal therapy in metastatic prostate cancer. Prostate; 2003 Sep 1;56(4):305-12
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Elevated serum progastrin-releasing peptide (31-98) level is a predictor of short response duration after hormonal therapy in metastatic prostate cancer.
  • BACKGROUND: The neuroendocrine (NE) pathway has been attracting attention as a mechanism for the androgen-independent progression because the neuropeptide provokes tumor growth and inhibits apoptosis under androgen-deprived milieu in prostate cancer cells.
  • METHODS: Serum ProGRP status was determined with an enzyme-linked immunosorbent assay (ELISA) in 460 men with benign and malignant prostatic diseases, chronic renal failure, and healthy controls.
  • Seventy patients with metastatic prostate cancer including four patients (5.7%) with NE carcinoma who underwent hormonal therapy were enrolled in the prognostic analyses by Cox proportional hazards model.
  • RESULTS: The serum status steadily shifted toward predominant expression of ProGRP with the progression of prostate cancer into metastatic and androgen-independent stages.
  • Serum ProGRP was the most significant predictor among pre-treatment factors in this model (P = 0.0094).
  • CONCLUSIONS: The neuropeptide precursor ProGRP is a distinct serum marker that is useful to know the NE milieu and provides prognostic information in patients with advanced prostate cancer.
  • Standard therapy for metastatic prostate cancer may make progress when further studies will clarify the causative link between serum ProGRP level and androgen-independent disease progression.
  • [MeSH-major] Biomarkers, Tumor / analysis. Gastrointestinal Hormones / analysis. Neoplasm Metastasis. Neoplasm Staging / methods. Peptide Fragments / analysis. Peptides / analysis. Prostatic Neoplasms / drug therapy. Prostatic Neoplasms / pathology. Recombinant Proteins / analysis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Androgens / pharmacology. Antineoplastic Agents, Hormonal / pharmacology. Drug Resistance, Neoplasm. Enzyme-Linked Immunosorbent Assay. Humans. Male. Middle Aged. Predictive Value of Tests. Prognosis. Prostate-Specific Antigen / analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Prostate cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2003 Wiley-Liss, Inc.
  • (PMID = 12858359.001).
  • [ISSN] 0270-4137
  • [Journal-full-title] The Prostate
  • [ISO-abbreviation] Prostate
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Androgens; 0 / Antineoplastic Agents, Hormonal; 0 / Biomarkers, Tumor; 0 / Gastrointestinal Hormones; 0 / Peptide Fragments; 0 / Peptides; 0 / Recombinant Proteins; 0 / pro-gastrin-releasing peptide (31-98); EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


31. Zachariou Z, Sieverts H, Eble MJ, Gfrörer S, Zavitzanakis A: IORT (intraoperative radiotherapy) in neuroblastoma: experience and first results. Eur J Pediatr Surg; 2002 Aug;12(4):251-4
MedlinePlus Health Information. consumer health - Neuroblastoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Intraoperative radiotherapy (IORT) permits the application of a single large radiation dose to a malignant mass at the time of surgery sparing adjacent normal tissue from irradiation.
  • Ultrasound, CT and MRI were performed and patients were treated with chemotherapy according to the NB90 protocol.
  • Localised radiation of the residual tumour was 8 - 10 Gy.
  • The follow-up time was 6 - 69 months (May 2001).
  • The clinical course of 2 patients was complicated by a renal artery stenosis and a mesenteric artery occlusion.
  • [MeSH-minor] Child. Child, Preschool. Combined Modality Therapy. Follow-Up Studies. Humans. Intraoperative Period. Neoplasm Staging. Retrospective Studies. Second-Look Surgery

  • Genetic Alliance. consumer health - Neuroblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12369003.001).
  • [ISSN] 0939-7248
  • [Journal-full-title] European journal of pediatric surgery : official journal of Austrian Association of Pediatric Surgery ... [et al] = Zeitschrift für Kinderchirurgie
  • [ISO-abbreviation] Eur J Pediatr Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


32. Graham JS, Falk S, Samuel LM, Cendros JM, Evans TR: A multi-centre dose-escalation and pharmacokinetic study of diflomotecan in patients with advanced malignancy. Cancer Chemother Pharmacol; 2009 Apr;63(5):945-52
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Patients with advanced solid malignant tumours, refractory to standard therapies, with adequate haematologic, renal and hepatic function, received diflomotecan administered as a 20 min intravenous infusion every 21 days.
  • Cohorts of six patients were recruited sequentially to one of three fixed starting dose groups-2, 4, or 7 mg, with drug administered by fixed-dose rather than dosing by body surface area.
  • Pharmacokinetic analyses revealed a less than dose-proportional increase in diflomotecan and for the two metabolites BN80942 and P-20, with a magnitude of P-20 exposure similar to the parent drug.
  • One minor response was observed in a patient with oesophageal cancer.
  • [MeSH-major] Camptothecin / analogs & derivatives. Neoplasms / drug therapy. Neoplasms / metabolism
  • [MeSH-minor] Administration, Oral. Adolescent. Adult. Aged. Breath Tests. Cytochrome P-450 CYP3A / analysis. Dose-Response Relationship, Drug. Erythromycin. Female. Humans. Infusions, Intravenous. Middle Aged. Neoplasm Staging. Prognosis. Survival Rate. Tissue Distribution. Treatment Outcome. Young Adult

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. Erythromycin .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18654747.001).
  • [ISSN] 1432-0843
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] Germany
  • [Chemical-registry-number] 63937KV33D / Erythromycin; EC 1.14.13.67 / CYP3A4 protein, human; EC 1.14.14.1 / Cytochrome P-450 CYP3A; QKT1LC4J1P / diflomotecan; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


33. Diagnosis and Therapy for Bone Metastasis of Malignant Tumors and Skeletal-Related Events Expert Group: [Diagnosis and treatment of bone metastasis of renal cancer: an expert consensus statement (2008 version)]. Zhonghua Zhong Liu Za Zhi; 2010 Apr;32(4):317-9
Hazardous Substances Data Bank. NICOTINAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Diagnosis and treatment of bone metastasis of renal cancer: an expert consensus statement (2008 version)].
  • [MeSH-major] Bone Neoplasms. Carcinoma, Renal Cell / therapy. Kidney Neoplasms / surgery
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Benzenesulfonates / therapeutic use. Humans. Interleukin-2 / analogs & derivatives. Interleukin-2 / therapeutic use. Neoplasm Staging. Niacinamide / analogs & derivatives. Pain / drug therapy. Pain / etiology. Phenylurea Compounds. Pyridines / therapeutic use. Recombinant Proteins / therapeutic use

  • Genetic Alliance. consumer health - Kidney cancer.
  • Genetic Alliance. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20510090.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] Consensus Development Conference; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzenesulfonates; 0 / Interleukin-2; 0 / Phenylurea Compounds; 0 / Pyridines; 0 / Recombinant Proteins; 25X51I8RD4 / Niacinamide; 9ZOQ3TZI87 / sorafenib; M89N0Q7EQR / aldesleukin
  • [Investigator] Ma JH
  •  go-up   go-down






Advertisement